Development and Validation of an Individualized Immune Prognostic Signature in Early-Stage Nonsquamous Non–Small Cell Lung Cancer
Bailiang Li(Stanford University), Ruijiang Li(Peking University), Maximilian Diehn(Stanford University), Yi Cui(Kunming University of Science and Technology)
Cited by 600
Related Papers
Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review
|Journal of Clinical Oncology|2018|925
Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients
|Nature Communications|2016|657
Liquid Biopsy for Advanced NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer
|Journal of Thoracic Oncology|2021|642